Lauriane Eberst

1.0k citations

38 papers · 415 indexed · h-index 10

Impact in

Oncology
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Research Studies
Pulmonary and Respiratory Medicine
- Brain Metastases and Treatment
- Sarcoma Diagnosis and Treatment

Papers in ⓘ

Reproductive Medicine 11
- Ovarian cancer diagnosis and treatment 11
Oncology 22
- Cancer Immunotherapy and Biomarkers 7
- Pancreatic and Hepatic Oncology Research 5
- Colorectal Cancer Treatments and Studies 4

Co-authors: Thomas Bachelot (3 shared papers)Caroline Bailleux (2 shared papers)Philippe A. Cassier (16 shared papers)Isabelle Treilleux (5 shared papers)C. Terret (8 shared papers)David Pérol (6 shared papers)Mehdi Brahmi (4 shared papers)Aurélien Marabelle (5 shared papers)
Journals: Journal of Clinical Oncology (10 papers)Annals of Oncology (7 papers)British Journal of Cancer (2 papers)The Oncologist (2 papers)Clinical Cancer Research (1 paper)
Partner nations: France Italy United States

In The Last Decade

Lauriane Eberst

35 papers receiving 409 citations

Peers

Countries citing papers authored by Lauriane Eberst

Since Specialization

Citations

This map shows the geographic impact of Lauriane Eberst's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lauriane Eberst with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lauriane Eberst more than expected).

Fields of papers citing papers by Lauriane Eberst

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lauriane Eberst. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lauriane Eberst. The network helps show where Lauriane Eberst may publish in the future.

Co-authors

The 25 scholars most cited alongside Lauriane Eberst, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Lauriane Eberst Line = papers co-authored together Lauriane Eberst links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 38 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Treatment strategies for breast cancer brain metastases British Journal of Cancer ·Caroline Bailleux, Lauriane Eberst, Thomas Bachelot	2020	151
2	Long-term efficacy of imatinib mesylate in patients with advanced Tenosynovial Giant Cell Tumor Scientific Reports ·F.G.M. Verspoor, M.J.L. Mastboom, Gerjon Hannink, Robert G. Maki, Andrew J. Wagner, Emmanuelle Bompas, Jayesh Desai, Antoîne Italiano, Beatrice Seddon, Winette T.A. van der Graaf, Jean‐Yves Blay, Mehdi Brahmi, Lauriane Eberst, Silvia Stacchiotti, Olivier Mir, Michiel A. J. van de Sande, Hans Gelderblom, Philippe A. Cassier	2019	46
3	MEDIPLEX: A phase 1 study of durvalumab (D) combined with pexidartinib (P) in patients (pts) with advanced pancreatic ductal adenocarcinoma (PDAC) and colorectal cancer (CRC). Journal of Clinical Oncology ·Philippe A. Cassier, Gwenaëlle Garin, Lauriane Eberst, Jean‐Pierre Delord, Sylvie Chabaud, C. Terret, Laure Montané, Anne-Sophie Bidaux, S. Laurent, Lise Jaubert, Céline Ferlay, Mathilde Bernardin, Séverine Tabone‐Eglinger, Laurence Gilles-Afchain, Christine Ménétrier‐Caux, Christophe Caux, Isabelle Treilleux, David Pérol, Carlos Gomez‐Roca	2019	40
4	The CSF-1R inhibitor pexidartinib affects FLT3-dependent DC differentiation and may antagonize durvalumab effect in patients with advanced cancers Science Translational Medicine ·Aurélien Voissière, Carlos Gomez‐Roca, Sylvie Chabaud, Céline Rodriguez, Axelle Nkodia, Justine Berthet, Laure Montané, Anne-Sophie Bidaux, Isabelle Treilleux, Lauriane Eberst, C. Terret, Iphigénie Korakis, Gwenaëlle Garin, David Pérol, Jean‐Pierre Delord, Christophe Caux, Bertrand Dubois, Christine Ménétrier‐Caux, Nathalie Bendriss‐Vermare, Philippe A. Cassier	2024	32
5	The PLA2R1-JAK2 pathway upregulates ERRα and its mitochondrial program to exert tumor-suppressive action Oncogene ·Audrey Griveau, Guillaume Devailly, Lauriane Eberst, Naveenan Navaratnam, Benjamin Le Calvé, M. Ferrand, Peter Faull, Arnaud Augert, R. Dante, Jean-Marc Vanacker, David Vindrieux, David Bernard	2016	19
6	Randomized phase III trial in MMR deficient (MMRd) endometrial cancer (EC) patients comparing chemotherapy (CT) alone versus dostarlimab in first line advanced/metastatic setting: DOMENICA study (GINECO-EN105b/ENGOT-en13 study). Journal of Clinical Oncology ·Florence Joly, Isabelle Laure Ray-Coquard, María Jesús Rubio, Xavier Paolettí, Alison Davis, Emma Hudson, Domenica Lorusso, Germana Tognon, Ursula Hasler-Strub, Chel Hun Choi, Mehmet Ali Vardar, Stéphanie Lheureux, Toon Van Gorp, David S.P. Tan, Fabian Trillsch, Lauriane Eberst, Céline Lescure, Anne‐Claire Hardy‐Bessard, Marie Chaix	2023	15
7	Immune checkpoint inhibitor-based combinations: is dose escalation mandatory for phase I trials? Annals of Oncology ·Victor Simmet, Lauriane Eberst, Aurélien Marabelle, Philippe A. Cassier	2019	14
8	Complete Laparoscopic Interval Debulking Surgery for Advanced Ovarian Cancer Achieves Similar Survival Outcomes to Open Approach: A Propensity-Matched Study Journal of Investigative Surgery ·Lise Lecointre, Madeleine Pellerin, Aïna Venkatasamy, Thibaut Fabacher, Lauriane Eberst, Justine Gantzer, Floriane Jochum, Émilie Faller, Thomas Boisramé, Denis Querleu, Chérif Akladios	2022	11
9	A first in human, phase I trial of NP137, a first-in-class antibody targeting netrin-1, in patients with advanced refractory solid tumors Annals of Oncology ·Philippe A. Cassier, Lauriane Eberst, G. Garin, Yann Courbebaisse, C. Terret, M. Robert, Jean‐Sébastien Frenel, Stéphane Depil, Jean‐Pierre Delord, David Pérol, Isabelle Laure Ray-Coquard, Anne-Sophie Bidaux, Séverine Tabone‐Eglinger, Laurence Gilles-Afchain, Isabelle Treilleux, Q. Wang, Benjamin Ducarouge, Patrick Mehlen, Jean‐Yves Blay, Carlos Gomez‐Roca	2019	10
10	Detailed overview on rare malignant ovarian tumors Bulletin du Cancer ·Stefanie Aust, Lauriane Eberst, Olivier Trédan, Christine Rousset‐Jablonski, Isabelle Treilleux, Pierre Méeus, Nicolás Chopin, Fred Beurrier, Amandine Charreton, Daval Véronique, Amina Hallouz, A. Coulon, Alexis Ricoeur, Charles Mastier, Amine Bouhamama, S. Racadot, Mojgan Devouassoux‐Shisheboran, Véronique Haddad, Isabelle Ray‐Coquard	2020	9
11	Therapeutic relevance of molecular screening program in patients with metastatic sarcoma: Analysis from the ProfiLER 01 trial Translational Oncology ·Patrick Arnaud‐Coffin, Mehdi Brahmi, Hélène Vanacker, Lauriane Eberst, Olivier Trédan, Valéry Attignon, Daniel Pissaloux, Emilie Sohier, Philippe A. Cassier, Gwenaëlle Garin, David Pérol, Jean‐Yves Blay, Armelle Dufresne	2020	8
12	Basics of immunotherapy for epithelial ovarian cancer Journal of Gynecology Obstetrics and Human Reproduction ·Virginie Collin-Bund, Henri Azaïs, Sabrina Bibi‐Triki, Lise Lecointre, Sarah Bétrian, Martina Aida Ángeles, Lauriane Eberst, Émilie Faller, Thomas Boisramé, Sofiane Bendifallah, Chérif Akladios, Élise Deluche	2021	8
13	Phase I Study of Ramucirumab Plus Merestinib in Previously Treated Metastatic Colorectal Cancer: Safety, Preliminary Efficacy, and Pharmacokinetic Findings The Oncologist ·Mansoor N. Saleh, Philippe A. Cassier, Lauriane Eberst, Gurudatta Naik, Van K. Morris, Shubham Pant, C. Terret, Ling Gao, Amanda Long, Huzhang Mao, Samuel McNeely, Erin K. Wagner, Roberto Carlesi, Siqing Fu	2020	8
14	Uncovering the Translational Regulatory Activity of the Tumor Suppressor BRCA1 Cells ·Élise Berthel, Anne Vincent, Lauriane Eberst, Adrián Gabriel Torres, Estelle Dacheux, Catherine Rey, Virginie Marcel, Hermes Paraqindes, Joël Lachuer, Frédéric Catez, Lluı́s Ribas de Pouplana, Isabelle Treilleux, Jean‐Jacques Diaz, Nicole Dalla Venezia	2020	6
15	A Phase 1 dose-escalation study to evaluate safety, pharmacokinetics and pharmacodynamics of AsiDNA, a first-in-class DNA repair inhibitor, administered intravenously in patients with advanced solid tumours British Journal of Cancer ·Christophe Le Tourneau, Jean‐Pierre Delord, Nuria Kotecki, Édith Borcoman, Carlos Gomez‐Roca, S. Hescot, Christiane Jungels, Anne Vincent‐Salomon, Vincent Cockenpot, Lauriane Eberst, Audrey Molé, Wael Jdey, Françoise Bono, Véronique Trochon-Joseph, Hélène Toussaint, Christelle Zandanel, Olga Adamiec, Olivier Beaumont, Philippe A. Cassier	2020	5
16	Ciblage thérapeutique de la voie Notch en oncologie Bulletin du Cancer ·Mehdi Brahmi, Olivia Bally, Lauriane Eberst, Philippe A. Cassier	2017	5
17	AXLerate-OC/GOG-3059/ENGOT OV-66: Results of a phase 3, randomized, double-blind, placebo/paclitaxel-controlled study of batiraxcept (AVB-S6-500) in combination with paclitaxel in patients with platinum-resistant recurrent ovarian cancer. Journal of Clinical Oncology ·Katherine C. Fuh, Zaza Tsitsishvili, Thomas Reid, Ugo De Giorgi, Lauren Hand, Rebecca Bowen, Devin Miller, Christof Vulsteke, Sudarshan Sharma, Anita Chudecka-Głaz, Joyce F. Liu, Lauriane Eberst, Robert Neff, Peter Lim, David A. Iglesias, Tilley Jenkins Vogel, Tashanna Myers, Antonio González-Martı́n, (unknown)	2024	4
18	Xevinapant Combined with Pembrolizumab in Patients with Advanced, Pretreated, Colorectal and Pancreatic Cancer: Results of the Phase Ib/II CATRIPCA Trial Clinical Cancer Research ·Allison Voisin, C. Terret, Camille Schiffler, Anne-Sophie Bidaux, Hélène Vanacker, Marlène Perrin-Niquet, Maud Barbery, Armelle Vinceneux, Lauriane Eberst, Pierre Stéphan, Gwenaële Garin, Dany Spaggiari, David Pérol, Yenkel Grinberg‐Bleyer, Philippe A. Cassier	2024	3
19	Prevention of brain metastases in human epidermal growth factor receptor 2-positive breast cancer Current Opinion in Oncology ·Lauriane Eberst, Caroline Bailleux, Thomas Bachelot	2020	2
20	Projecting overall survival in health-economic models: uncertainty and maturity of data Current Medical Research and Opinion ·Stéphane Roze, Nicolas Bertrand, Lauriane Eberst, Isabelle Borget	2023	2

About Lauriane Eberst

Lauriane Eberst is a scholar working on Reproductive Medicine, Oncology, Obstetrics and Gynecology, Pulmonary and Respiratory Medicine and Hepatology, having authored 38 papers that have together received 415 indexed citations. Recurring topics across this work include Ovarian cancer diagnosis and treatment (11 papers), Cancer Immunotherapy and Biomarkers (7 papers), Pancreatic and Hepatic Oncology Research (5 papers), Endometrial and Cervical Cancer Treatments (4 papers), Colorectal Cancer Treatments and Studies (4 papers), Brain Metastases and Treatment (3 papers), Cancer Genomics and Diagnostics (3 papers) and Health Systems, Economic Evaluations, Quality of Life (3 papers). The work is most often cited by research in Oncology (215 citations), Pulmonary and Respiratory Medicine (164 citations), Reproductive Medicine (36 citations), Immunology (82 citations) and Genetics (37 citations). Lauriane Eberst has collaborated with scholars based in France, Italy and United States. Frequent co-authors include Thomas Bachelot, Caroline Bailleux, Philippe A. Cassier, Isabelle Treilleux, C. Terret, David Pérol, Mehdi Brahmi, Aurélien Marabelle, Jean‐Pierre Delord and Christine Ménétrier‐Caux. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, British Journal of Cancer, The Oncologist and Clinical Cancer Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact